Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Issues Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) announced its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, FiscalAI reports.

Calidi Biotherapeutics Stock Performance

NYSEAMERICAN:CLDI traded down $0.02 during mid-day trading on Friday, hitting $0.17. The stock had a trading volume of 2,492,460 shares, compared to its average volume of 2,632,261. The stock has a market capitalization of $1.90 million, a price-to-earnings ratio of -0.03 and a beta of 1.38. The company has a 50 day simple moving average of $0.28 and a 200-day simple moving average of $0.88. Calidi Biotherapeutics has a 52 week low of $0.16 and a 52 week high of $19.20. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Calidi Biotherapeutics

Large investors have recently made changes to their positions in the company. DRW Securities LLC bought a new stake in shares of Calidi Biotherapeutics during the fourth quarter valued at approximately $173,000. Virtu Financial LLC acquired a new stake in Calidi Biotherapeutics in the 4th quarter valued at approximately $25,000. Warberg Asset Management LLC acquired a new stake in Calidi Biotherapeutics in the 3rd quarter valued at approximately $28,000. Finally, Geode Capital Management LLC raised its stake in Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares in the last quarter. Institutional investors and hedge funds own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.